Peptide · GIP, GLP-1 and glucagon receptor agonist
Retatrutide
An investigational once-weekly peptide that acts on three hormone receptors, in late-stage clinical trials for obesity and type 2 diabetes.
In clinical trialsBeing tested in regulated trials. Not authorised for sale.
- Legal status · US
- In clinical trials
- Evidence in people
- Molecule
- GIP, GLP-1 and glucagon receptor agonist
- In sport
- Not named on the WADA list
- Status checked
Regulatory status · United States
This describes the position in the United States. Rules in Netherlands differ; an approved peptide medicine there is in its national register.
Not approved anywhere as of the date above. It is being studied in phase 3 trials, and its developer runs a pre-approval expanded-access programme under FDA rules. Anything sold as "retatrutide" today is not an authorised product.
What changed, and when
Phase 3 trial programme begins in obesity and type 2 diabetes.
Still investigational; pre-approval expanded access listed on ClinicalTrials.gov.
What to be careful about
Trial results describe the manufacturer’s product given under medical supervision. A vial sold online as "research" retatrutide is not that product, and nobody has checked what is in it.
Why there is no dosing information here
There is no authorised human dose to report. Any figure printed here would come from a vendor or a forum, and would look exactly like one taken from an approved label — which is the specific confusion that makes this category dangerous.
Sources
Regulatory positions change. This page states the date it describes, and nothing on it is legal or medical advice.